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Abstract Background Treatment of chronic anal fissure
(CAF) by fissurectomy with botulinum toxin A (BTA)
injection results in a healing rate of greater than 90%. BTA
injection, however, can cause incontinence and perianal
sepsis. The decrease in sphincter pressure following topi-
cal treatment with 2% diltiazem cream (DTC) is compara-
ble to that following BTA injection but with potentially
fewer complications and at less cost. We report the short-
term results of a pilot study comparing fissurectomy with
BTA and fissurectomy followed by DTC for the treatment
of CAF. Methods The recorded outcomes of CAF follow-
ing treatment with the two methods were analysed retro-
spectively. Patients underwent either fissurectomy fol-
lowed by injection of 40 U BTA into the internal sphinc-
ter (group A) or fissurectomy followed by the perianal
application of DTC twice daily for 8 weeks (group B).
Symptom resolution and treatment side effects at the ini-
tial follow-up were compared. Results Demographics, fis-
sure characteristics and the number of multiparous women
between the two groups were comparable. At a median
follow-up of 12 weeks (range 8–20 weeks), the two
groups had similar rates of complete symptom resolution
(group A, 25/28, 89.3%; group B, 19/23, 82.6%;
p=0.7739), with minor side effects. Conclusions In this
small pilot study fissurectomy combined with chemical
sphincterotomy resulted in high short-term fissure healing
rates. The study also suggested that fissurectomy fol-
lowed by 8 weeks of topical DTC may be as good as fis-
surectomy with BTA injection in the treatment of CAF. A
prospective study, adequately powered to determine the
significance of differences is needed.
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Introduction
The gold standard for healing rates in the treatment of
chronic anal fissure is lateral sphincterotomy [1]. Despite
the high healing rates associated with the procedure, the
recognized risk of incontinence continues to prompt a
shift from surgical to medical means of reducing internal
anal sphincter (IAS) resting pressure to achieve fissure
healing [2–4]. Medical agents include topical glyceryl
trinitrate (GTN), calcium channel blockers such as topi-
cal diltiazem cream (DTC) and more recently, botulinum
toxin A (BTA) injection into the IAS.
Diltiazem has been shown, both in oral and topical
form, to reduce resting anal pressure in patients with anal
disease, and when utilized as treatment for fissures,
results in a healing rate of approximately 70% [5–7]. It
acts by calcium channel inhibition thus relaxing smooth
muscle. This results in vasodilation and increased blood
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flow as well as anal sphincter relaxation. The oral prepa-
ration, however, results in a more significant change in
blood pressure and the topical 2% preparation may be
preferred [8].
More recently, BTA injection into the IAS has also
been shown to decrease mean resting pressure and has
proved efficacious in the treatment of chronic anal fis-
sures [9–14]. Development in the understanding of this
drug’s mode of action suggests that it binds rapidly to the
neuromuscular junction and prevents the release of
acetylcholine. Repeat administration of the toxin A may,
however, result in antibody production in up to 10% of
patients. Such patients will then develop resistance to
further treatment. The results of treatment may also
decrease over the long term [14, 15].
All the treatment modalities discussed above will
have nonresponders who may require additional treat-
ment. It may not be necessary to proceed immediately to
surgical sphincterotomy.
In 2002, Engel et al. [16] successfully tested the
hypothesis that chronic fissures unresponsive to medical
treatment should be regarded as areas of unstable scar tis-
sue in an environment of reduced tissue perfusion result-
ing from IAS spasm. In a prospective study of 17 patients
who had failed topical isosorbide dinitrate (IDN) treat-
ment for chronic anal fissures, a 100% fissure healing
rate was achieved when fissurectomy was combined with
further topical 1% IDN applied four to six times daily.
The patients were followed up initially for 6 weeks after
the procedure. A further long-term telephone follow-up
at a median 29 months showed no recurrence, presum-
ably of symptoms.
This hypothesis was further supported by a subsequent
study of fissurectomy combined with BTA injection,
which showed a 93% fissure healing rate at 16 weeks fol-
low-up [12]. BTA is, however, relatively costly and there
is emerging data on complications of incontinence and
perianal sepsis with its use [10, 17–19]. Recent newspa-
per reports of complications following its use for cosme-
sis have resulted in patients questioning its utilization and
asking for alternatives (International Herald Tribune, 25
January 2008; HeraldNet, Washington, 20 August 2008).
In the present study, we compared the results of fis-
surectomy followed by topical 2% DTC with those of fis-
surectomy combined with BTA injection in the treatment
of anal fissures that had already failed to respond to med-
ical management.
Methods
The outcomes of treatment in all patients with medically
resistant chronic anal fissures who had undergone either
fissurectomy followed by 8 weeks of topical perianal
DTC or fissurectomy combined with BTA injection was
studied retrospectively. All patients in this study had
failed previous treatment for at least 6 weeks with either
topical GTN or 2% DTC. Failed treatment was defined as
recurrent or unchanged anal pain and/or bleeding
assessed and attributed to chronic anal fissure. At the
time of treatment all patients had clinically evident
chronic fissures characterized by fibrotic edges with or
without a sentinel pile and hypertrophic anal papilla, and
associated with pain and/or bleeding at defaecation. The
choice of pharmacological adjunct to fissurectomy was
based on clinicians’ preference based on their experi-
ences and past and newly implemented hospital procure-
ment policy.
All patients underwent day-case general anaesthetic
procedures between January 2005 and June 2006 inclusive.
Group A patients underwent surgical knife excision
of the fibrotic fissure edges and, where present, the asso-
ciated sentinel pile. The fissure base was curetted, avoid-
ing damage to the internal sphincter muscle. BTA
(BOTOX; Allergan, Marlow, UK) was then injected into
the IAS on both sides of the fissure (20 U per side, total
40 U). Group B patients underwent similar fissurectomy,
but after the procedure were provided with 2% DTC
(Anoheal; SLA Pharma, Watford, UK). They received
written instructions to squeeze 1 inch (2–2.5 cm) onto the
tip of a finger and apply the cream to the perianal margin
and into the anal canal twice daily for 8 weeks. The
cream was supplied as 30-g tubes with each tube expect-
ed to last about 4 weeks. Patients in both groups were
discharged home the same day with Fybogel (one sachet
twice daily for 6 weeks and 15 ml lactulose twice daily
for 6 weeks). No other topical or oral agents such as
metronidazole were prescribed.
All patients underwent clinic follow-up at a median
of 12 weeks after surgery (range 8–20 weeks). A consult-
ant surgeon or a supervised senior registrar in the clinic
assessed outcome. This involved direct questioning to
establish the persistence or resolution of pain and/or
bleeding at defaecation. Gentle eversion of the anal mar-
gin was performed to assess fissure healing. Grades or
degrees of fissure healing were not included as end-
points in this study due to its subjective nature. In the
same vein, complete symptom resolution with a near-
healed fissure would not necessarily mandate further
intervention; hence the omission of visual evidence of
fissure healing as an end-point. Incontinence was not
formally assessed by the use of standardized tools or
investigation.
All patients with symptoms and signs of failed treat-
ment were offered further treatment with either DTC for
a further 6 weeks or lateral sphincterotomy.
332 Tech Coloproctol (2008) 12:331–336
Statistical analysis
Differences in demographic and fissure characteristics
were compared using the Mann-Whitney, chi-squared
and Fisher’s exact tests, and differences in outcome
expressed as percentages were analysed using Fisher’s
exact test.
Results
Over the period studied, 51 patients with medically
resistant anal fissures were treated either by fissurectomy
combined with BTA injection (group A, n=28) or by fis-
surectomy followed by 2% DTC (group B, n=23). There
was no statistically significant difference between the
groups with respect to age, gender or fissure characteris-
tics or, among the females, multiparity (Table 1). None of
the patients had inflammatory bowel disease.
At initial follow-up, there was no statistically signifi-
cant difference between the two groups with respect to
patients who were completely symptom-free (group A,
25/28, 89.3%; group B, 19/23, 82.6%; p=0.7739). Of the
three symptomatic patients in group A with persisting
symptoms of anal pain and/or bleeding, all were
observed to have unhealed fissures. Two patients were
offered, and accepted, topical 2% DTC treatment for a
further 6 weeks. One of these patient was completely
symptom-free at the end of that period. The other two
patients in this group therefore eventually underwent lat-
eral sphincterotomy. In group B, all of the four sympto-
matic patients were observed to have unhealed fissures
and were offered further topical 2% DTC. Two of these
patients were completely symptom-free after a further 6
weeks of treatment. The other nonresponders did not
attend further scheduled clinic follow-up sessions.
Two patients from group A complained of minor pas-
sive postdefaecatory faecal soiling lasting about 2 weeks
during treatment whereas three patients in group B com-
plained of pruritus ani, which resolved on completion of
treatment.
There were no incidences of perianal sepsis or
haematoma following BTA injection in this study, nor
were there any reports of headache or dizziness with
DTC use.
Discussion
This study demonstrates that fissurectomy followed by a
short course of twice-daily topical 2% DTC may be as
good as fissurectomy combined with BTA in the treat-
ment of medically resistant fissure-in-ano at short-term
follow-up. It also suggests that high rates of fissure heal-
ing can be achieved if fissurectomy is combined with the
pharmacological sphincterotomy modalities investigated.
Chemical sphincterotomy shares the same goal as lat-
eral sphincterotomy without its possible long-term side
effects. It reduces the IAS spasm found with anal fis-
sures, resulting in a decrease in the mean IAS resting
pressure and an improvement in the arteriolar blood flow
to the posterior commissures of the lower anal canal
[20–22], thus logically creating an environment that
would promote healing of anal fissures.
Fissurectomy alone has been used to treat anal fis-
sures in children with success [23], but there are no
published studies on the use of fissurectomy alone as
treatment of anal fissures in adults. In the study in chil-
dren of fissurectomy, which was followed by a period of
prescribed gentle laxative use, a fissure healing rate of
81% was achieved. This may suggest that the clinically
significant component of the presented therapy is fis-
surectomy. In the absence of a fissurectomy-alone arm
in this comparative pilot study, we can only surmise at
this possibility. A few studies have investigated the use
of fissurectomy with posterior midline internal sphinc-
terotomy with acceptable results [24–27]. However,
Melange et al. found a 27% incidence of incontinence
for flatus or liquid stool and a 9.2% incidence of passive
soiling after the use of this technique [28]. This has his-
torically made clinicians wary of the use of this com-
bined modality. In performing fissurectomy in our prac-
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Table 1 Demographic and fissure characteristics of 51 patients with medically resistant fissure-in-ano
Fissurectomy/BTA (n=28) Fissurectomy/2% DTC (n=23) p value
Age (years)
Median 43.5 41 NSa
Range 23–46 25–52
Male/female 13/15 12/11 NSb
Anterior/posterior fissures 4/24 3/20 NSc
No. of multiparous females 3 1 NSb
aMann-Whitney U-test (p<0.05)
bChi-squared test (p<0.05)
cFisher’s exact test (p<0.05)
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much longer than the duration of the effect of GTN with
which a significant decrease in resting pressure lasting
only 90 minutes has been reported [32]. In the present
comparative study as well as in the authors’ early experi-
ence with these treatment modalities, no clinically
reported incontinence was found. This may reflect the
inconstancy of that side effect of BTA, as well as its
unpredictability.
It is interesting to note that two more patients in
group B were successfully treated with a further course
of 2% DTC. Also interesting to note were the failed
patients in group A who responded to DTC. It is unlike-
ly that this was related to the fissurectomy, but the
authors would suggest that the success of 2% DTC after
previous BTA treatment could merely be a cumulative
effect of the two treatments.
None of the patients who failed treatment with DTC
had anterior fissures, a finding that is at variance with the
observation of Griffin et al. that a high percentage of ante-
rior fissures failed treatment with DTC [33]. However,
their patients did not have the benefit of fissurectomy and
this surgical component of treatment may play a signifi-
cant role in healing of anterior chronic fissures.
Minor transient passive faecal soiling occurred in
two patients (7.1%) after BTA injection. This is compa-
rable to observed incidences documented in the litera-
ture. Both patients who experienced soiling were male
and had had banding of haemorrhoids more than 12
months prior to presentation. At initial presentation,
none of these patients had complained of faecal inconti-
nence. No formal incontinence assessment tools were,
however, applied as symptoms had resolved significant-
ly at follow-up. The authors can only surmise that the
faecal soiling was due to sustained lowered internal anal
sphincter pressure from BTA injection. The absence of
faecal soiling or incontinence amongst the DTC group is
difficult to explain. The authors would suggest that the
less-prolonged duration of sphincter relaxation with
DTC compared to BTA could explain this. Between
applications, a fluctuating degree of sphincter tone
recovery could be providing a certain degree of conti-
nence; however, this is open to debate. Pruritus ani
occurring with topical DTC, as observed in 13% of
patients in group B, could have been a local effect of the
moist application rather than a true side effect of the
medication. This was also transient.
Although the median study follow-up period of 12
weeks may seem short, this study evaluated initial out-
come only. As well as being a retrospective study with-
out planned long-term follow-up, this aspect of the study
reflects the practical aspects of management in a busy
colorectal service. Other limitations of this study could
be said to include its retrospective nature, nonrandomiza-
tice, utmost care is taken to avoid injury to the internal
sphincter fibres. Theoretically, fissurectomy alone
would not address IAS spasm, a most plausible reason
for ischaemia and nonhealing seen in chronic fissures,
and a possible cause of the debilitating postdefaecatory
anal pain associated with anal fissures. Fissurectomy,
however, creates fresh wound edges, creating in essence
an acute fissure. This manoeuvre would promote pri-
mary wound healing, an approach utilized in other areas
of surgery. When combined with chemical sphincteroto-
my, both possible reasons for fissure chronicity are
addressed and this may explain higher fissure healing
rates seen in studies of the treatment of chronic anal fis-
sures utilizing both approaches [16, 29], and in this
reported study.
Topical DTC has been shown to be superior to the
oral form with fewer side effects and better fissure heal-
ing rates. Its lower side-effect profile, as well as early
resolution of pain during its use, promotes compliance
[8, 30], an added benefit that allows patients to complete
the treatment. We found no complications such as
headache or dizziness following DTC use in this cohort
of patients.
BTA, on the other hand, only requires a single injec-
tion, thus eliminating the issue of compliance.
However, it may be perceived as expensive, with a 100-
U vial costing £143.92. The retail cost of a 30-g tube of
2% DTC is £49.92 in our hospital trust. Since an opened
vial has to be discarded when even only 40 U have been
used, one way to overcome the issue of cost would be to
schedule theatre lists such that at least two patients
requiring BTA injection are listed. However, two tubes
of DTC as utilized in this study still costs less for an ini-
tial course.
BTA has also been reported to result in perianal sep-
sis and sustained minor incontinence, which may persist
until the toxin’s effects have worn off by neuronal degen-
eration [10, 17]. There is one case report of long-term
faecal incontinence after BTA injection [18]. Short-term
side effects of BTA injection such as transient inconti-
nence to flatus and liquid stool, pain on injection and
haematoma are also well documented, but other longer-
term side effects are unknown [19]. Fortuitously, we
observed no perianal haematoma or sepsis after BTA
injection in this study.
Sustained lowering of resting IAS pressure after BTA
injection is also an obvious advantage. but therein lies its
weakness: any significant incontinence not acceptable to
a patient cannot be reversed until the effect of the drug
subsides. This risk is eliminated with a twice-daily appli-
cation of topical DTC which although short-acting, has
also been shown to achieve up to 5 hours of sustained
reduction in mean resting IAS pressure in one study [31],
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tion of patients and noninclusion of visual fissure healing
as an end-point. The two former issues are inherent to
retrospective studies and cannot be avoided. However,
they do not detract from the thought-provoking nature of
the study results. For the pathology in question, and con-
sidering the numbers of subjects studied in the published
papers referenced, the number of patients in this report is
not considered to be unduly small. This study cohort
would be a reasonable cohort size for a pilot study. A
larger prospective study with long-term end-points would
be desirable to confirm this study’s findings. However,
sample size and power calculations suggest that the num-
bers needed, based on equivalence of the modalities
being investigated, would be prohibitive.
In conclusion, even though this was a retrospective
study with a small cohort of patients, the authors feel
that significant issues have been raised. Firstly, the
results suggest that fissurectomy followed by 8 weeks of
topical treatment with 2% DTC may result in as high a
healing rate as fissurectomy combined with BTA in the
treatment of chronic anal fissures, without its risks. It
has acceptable side effects, which would aid compliance
with treatment. Secondly, our results, in addition to the
published data on fissurectomy as an adjunct to chemi-
cal sphincterotomy, suggest some of the highest treat-
ment rates for chronic anal fissures, except for surgical
sphincterotomy. These modalities of treatment may
become the standard for nonsphincterotomy treatment of
fissures. The subgroup of patients most likely to benefit
and who should be considered for such treatment may be
those with chronic anal fissures with abundant scar tis-
sue and those in whom surgical sphincterotomy would
be better avoided. A larger prospective randomized com-
parison of these treatment modalities, powered to detect
significant differences, is needed with long-term follow-
up to assess recurrence.
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Invited comment
In this issue Arthur and colleagues report a pilot study
comparing symptom resolution after combined fissurec-
tomy-diltiazem and fissurectomy-botulinum toxin in the
treatment of chronic anal fissure. Interestingly, in both
groups more than 80% of the patients were completely
symptom-free after 12 weeks. The authors concluded
that both treatment strategies do not differ in terms of
healing rate.
The treatment of chronic anal fissures is still chal-
lenging. Conservative treatment with topical nitrates or
calcium channel blockers is often unsatisfactory.
Although lateral internal sphincterotomy is still the sur-
gery of choice for refractory anal fissures this procedure
is accompanied by a considerable risk of incontinence
[1]. Today, increased tonicity of the internal sphincter is
blamed for anal fissures. Tonic contraction of the inter-
nal anal sphincter is mediated by sympathetic innerva-
tions, and the sphincter stays in a state of partial contrac-
tion relaxing in response to rectal distension. Several
reports have documented elevated resting anal pressures
in patients with fissure, with values above 90 mmHg.
Additionally, the elevated anal pressure causes
ischaemia of the posterior commissure and reduces the
anodermal blood flow. The combined concept of sphinc-
ter spasm and reduced anodermal blood flow explains
how surgical disruption of the internal anal sphincter
allows the fissure to heal (anal pressure decreases with a
rise in anal blood flow) [2, 3].
From this background the use of botulinum toxin is rea-
sonable and justified. Botulinum toxin in the treatment of
chronic anal fissures in nonsurgical settings and in combi-
nation with fissurectomy has been reported to show prom-
ising results in terms of healing rates [4, 5]. Fissurectomy,
as a wound debridement, removes the bradytrophic scar tis-
sue and supports wound healing. The additional injection
of botulinum toxin decreases the tonus of the internal anal
sphincter temporarily leading to an increased anal blood
flow. The effect of botulinum toxin is similar to that of sur-
gical sphincterotomy without the disadvantage of anatomi-
cal disruption of the internal anal sphincter. However, bot-
ulinum toxin is extremely expensive and its use is not with-
out risk. Besides temporary incontinence for air and stool,
other side effects have been reported, including necrotizing
fasciitis, generalized muscular weakness, perianal throm-
bosis and the possibility of antibody production [3].
From this study two important questions in the treat-
ment of chronic anal fissures arise. First, is the usage of
botulinum toxin for chronic anal fissures overrated?
Second, does fissurectomy without combined treatment
achieve similar healing rates? We do not have the final
answers yet and are looking forward to prospective ran-
domized trials comparing fissurectomy alone versus
combined strategies.
C. Soll, D. Hahnloser ()
Department of Visceral and Transplantation Surgery
University Hospital
Zurich, Switzerland
E-mail: dieter.hahnloser@usz.ch
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